Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Murray Epstein, MD

Articles by Murray Epstein, MD

Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors

ByMurray Epstein, MD,Paula J. Alvarez, RPh, MPH, MBA,Nancy L. Reaven, MA,Susan E. Funk, MBA, FACHE,Karen J. McGaughey, PhD,Melanie S. Brenner, PharmD, BCPS,Wade Benton, PharmD,Ladan Golestane

August 31st 2016

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

ByMurray Epstein, MD,Nancy L. Reaven, MA,Susan E. Funk, MBA,Karen J. McGaughey, PhD,Nina Oestreicher, PhD,John Knispel, MD

September 16th 2015

Latest Updated Articles

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors
Published: September 16th 2015 | Updated:
Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors
Published: August 31st 2016 | Updated:

Trending on AJMC

Withdrawal of Aid Could Cause Millions of Lives Lost to HIV

EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy

Recent FDA Approvals Expand Dermatology Options for Patients With Skin of Color

Stronger Primary Care, Oncology Partnerships May Improve Patient Outcomes: Mark Fendrick, MD

FDA Approves Second Generic Mifepristone Pill for Abortion

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

© 2025 MJH Life Sciences^®

All rights reserved.